Erik Thiele Orberg

Erik Thiele Orberg

Auto-generated profile, based on publicly available information

Erik Thiele Orberg

Clinic and Polyclinic for Internal Medicine III, University Hospital Regensburg, Regensburg, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2025 in Med
Verified
Journal Article
Open access
MPMarkus Perl
Markus Perl
MFMatthias A. Fante
Matthias A. Fante
KHKonstantin Herfeld
Konstantin Herfeld
JSJulian N. Scherer
Julian N. Scherer
HPHendrik Poeck
Hendrik Poeck
EOErik Thiele Orberg
Erik Thiele Orberg
The human gut microbiome shapes local and systemic immune responses and influences cancer immunotherapy outcomes. Microbial metabolites, including short-chain and branched-chain fatty acids, bile acids, tryptophan derivatives, and others, influence anti-tumor immunity by modulating immune cells, tumor growth, and the tumor microenvironment. These metabolites impact the efficacy of immune checkpoint inhibitors, allogeneic stem cell transplantation, chimeric antigen receptor T cell therapies, and immune-related adverse events. However, interindividual microbiome variability, antibiotic exposure, and the context-dependent pro- and anti-inflammatory effects of metabolites present significant challenges for clinical translation. Microbiome-based therapies, including live biotherapeutic products, dietary modifications (such as prebiotics), and synthetic metabolite compounds (postbiotics), are being developed for use in combination with immunotherapy. This review outlines how metabolites influence immunotherapy outcomes and discusses translational approaches to harness them for clinical practice. Future research should focus on validating metabolite-based biomarkers and tailoring metabolite-based interventions to enhance efficacy and reduce toxicity across different immunotherapies.

26 November 2021 in Science Immunology
Verified
Journal Article
Closed access
AWAdam Wahida
Adam Wahida
MMMadeleine Müller
Madeleine Müller
AHAndreas Hiergeist
Andreas Hiergeist
BPBastian Popper
Bastian Popper
Katja SteigerKatja Steiger
Katja Steiger
MYMonica Yabal
Monica Yabal
In XIAP deficiency, ileitis is driven by TNFR1- and TNFR2-dependent targeting of TLR5-expressing Paneth and dendritic cells.

3 January 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
EOErik Thiele Orberg
Erik Thiele Orberg
EMElisabeth Meedt
Elisabeth Meedt
AHAndreas Hiergeist
Andreas Hiergeist
JXJinling Xue
Jinling Xue
PHPaul Heinrich
Paul Heinrich
HPHendrik Poeck
Hendrik Poeck

21 February 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
MCMarie Czech
Marie Czech
SSSophia Schneider
Sophia Schneider
NPNina Peltokangas
Nina Peltokangas
NKNadia El Khawanky
Nadia El Khawanky
SGSakhila Ghimire
Sakhila Ghimire
RZRobert Zeiser
Robert Zeiser
Acute graft-versus-host disease (aGVHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT), for which therapeutic options are limited. Strategies to promote intestinal tissue tolerance during aGVHD may improve patient outcomes. Using single-cell RNA sequencing, we identified a lipocalin-2 (LCN2)–expressing neutrophil population in mice with intestinal aGVHD. Transfer of LCN2-overexpressing neutrophils or treatment with recombinant LCN2 reduced aGVHD severity, whereas the lack of epithelial or hematopoietic LCN2 enhanced aGVHD severity and caused microbiome alterations. Mechanistically, LCN2 induced insulin-like growth factor 1 receptor (IGF-1R) signaling in macrophages through the LCN2 receptor SLC22A17, which increased interleukin-10 (IL-10) production and reduced major histocompatibility complex class II (MHCII) expression. Transfer of LCN2-pretreated macrophages reduced aGVHD severity but did not reduce graft-versus-leukemia effects. Furthermore, LCN2 expression correlated with IL-10 expression in intestinal biopsies in multiple cohorts of patients with aGVHD, and LCN2 induced IGF-1R signaling in human macrophages. Collectively, we identified a LCN2-expressing intestinal neutrophil population that reduced aGVHD severity by decreasing MHCII expression and increasing IL-10 production in macrophages. This work provides the foundation for administration of LCN2 as a therapeutic approach for aGVHD.

20 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SGSascha Göttert
Sascha Göttert
EOErik Thiele Orberg
Erik Thiele Orberg
KFKaiji Fan
Kaiji Fan
PHPaul Heinrich
Paul Heinrich
DMDiana M. Matthe
Diana M. Matthe
HPHendrik Poeck
Hendrik Poeck
Changes in the intestinal microbiome and microbiota-derived metabolites predict clinical outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we report that desaminotyrosine (DAT), a product of bacterial flavonoid metabolism, correlates with improved overall survival and reduced relapse rates in patients receiving allo-HSCT. In preclinical mouse models, treatment with synthetic DAT prevents graft-versus-host disease by protecting the intestinal barrier and promoting intestinal regeneration and contributes to graft-vs.-leukemia responses. DAT´s beneficial effects on intestinal regeneration remain effective despite broad-spectrum antibiotics-induced dysbiosis, also when administered by fecal microbiota transfer with flavonoid-degrading F. plautii. Mechanistically, DAT promotes mTORC1-dependent activation and proliferation of intestinal stem cells, with concomitant engagement of the innate immune receptor STING required to mitigate metabolic stress and maintain an undifferentiated stem cell state independently of type-I interferon responses. Additionally, DAT can skew T cells towards an effector phenotype to modulate graft-versus-leukemia responses. Our data uncover DAT’s dual, tissue- and immune-modulating properties and underscore its potential in precision microbiome-based therapies to improve tissue regeneration and minimize immune-mediated side effects.

19 February 2026 in Blood
Verified
Journal Article
Open access
EKEKIN ECE GURER KLUGE
EKIN ECE GURER KLUGE
EMElisabeth Meedt
Elisabeth Meedt
JFJulia Feicht
Julia Feicht
KCKedi Cao
Kedi Cao
AHAndreas Hiergeist
Andreas Hiergeist
SGSakhila Ghimire
Sakhila Ghimire
Calprotectin, a calcium- and zinc-binding protein that comprises the subunits S100A8 and S100A9, has been extensively studied as a biomarker of gastrointestinal (GI) inflammation through fecal and serum analyses. However, its role in intestinal tissue remains poorly understood because of the limited availability of biopsy specimens. In this study, we analyzed S100A8 and S100A9 messenger RNA (mRNA) expression in 579 intestinal biopsy specimens from allogeneic stem cell transplantation recipients and observed a strong association with acute GI graft-versus-host disease (aGI-GVHD; P< .001). Neutrophil infiltration correlated with the severity of aGI-GVHD (P< .001), and calprotectin expression was strongly linked to Toll-like receptor 4 (TLR4; P< .001) and TLR2 (P< .001) expression. Both TLR4 and aGI-GVHD were associated with elevated calprotectin mRNA levels (P< .001). When patients received broad-spectrum antibiotics at disease onset, calprotectin expression was suppressed (S100A8, P = .001; S100A9, P = .01). GI site–specific differences in calprotectin expression were identified: during severe aGI-GVHD, levels increased up to 30-fold in the small intestine and up to fivefold in the large intestine with respect to mild or no aGI-GVHD, whereas under homeostasis, the large intestine exhibited higher baseline calprotectin (P = .001). The high clinical relevance of this finding is evident from the observation that calprotectin expression was prognostic for transplant-related mortality. Our study suggests that (1) calprotectin is a potential biopsy biomarker in aGI-GvHD and (2) calprotectin expression and neutrophil infiltration possibly indicate translocation of microbiota, which (3) may be modulated by antibiotics.